Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$37.81 - $52.4 $260,510 - $361,036
6,890 Added 6.0%
121,635 $6.37 Million
Q1 2024

May 03, 2024

BUY
$33.68 - $41.95 $21,252 - $26,470
631 Added 0.55%
114,745 $4.67 Million
Q4 2023

Feb 08, 2024

BUY
$33.32 - $42.1 $69,139 - $87,357
2,075 Added 1.85%
114,114 $4.22 Million
Q3 2023

Nov 09, 2023

SELL
$36.46 - $44.03 $142,303 - $171,849
-3,903 Reduced 3.37%
112,039 $4.28 Million
Q2 2023

Aug 07, 2023

SELL
$30.28 - $38.74 $160,998 - $205,980
-5,317 Reduced 4.38%
115,942 $4.18 Million
Q1 2023

May 01, 2023

BUY
$32.86 - $55.7 $997,531 - $1.69 Million
30,357 Added 33.4%
121,259 $4.63 Million
Q4 2022

Feb 07, 2023

SELL
$40.06 - $59.44 $327,971 - $486,635
-8,187 Reduced 8.26%
90,902 $5.17 Million
Q3 2022

Oct 25, 2022

SELL
$38.53 - $51.78 $36,603 - $49,191
-950 Reduced 0.95%
99,089 $3.92 Million
Q2 2022

Aug 08, 2022

BUY
$37.35 - $48.3 $8,515 - $11,012
228 Added 0.23%
100,039 $4.4 Million
Q1 2022

May 06, 2022

SELL
$31.97 - $41.06 $53,869 - $69,186
-1,685 Reduced 1.66%
99,811 $3.98 Million
Q4 2021

Feb 08, 2022

SELL
$31.82 - $40.75 $120,725 - $154,605
-3,794 Reduced 3.6%
101,496 $4.08 Million
Q3 2021

Oct 28, 2021

BUY
$38.47 - $46.42 $213,393 - $257,491
5,547 Added 5.56%
105,290 $4.28 Million
Q2 2021

Jul 27, 2021

BUY
$38.84 - $51.31 $184,218 - $243,363
4,743 Added 4.99%
99,743 $4.53 Million
Q1 2021

May 03, 2021

SELL
$39.51 - $51.45 $277,873 - $361,847
-7,033 Reduced 6.89%
95,000 $3.96 Million
Q4 2020

Feb 04, 2021

BUY
$25.81 - $43.62 $2.63 Million - $4.45 Million
102,033 New
102,033 $4.36 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Texas Permanent School Fund Portfolio

Follow Texas Permanent School Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

News

Stay updated on Texas Permanent School Fund with notifications on news.